Day D G

Day D G, Sharpe E D, Atkinson M J, Stewart J A, Stewart W C

This study validated a glaucoma treatment satisfaction survey, finding satisfaction correlates with perceived effectiveness, side effects (especially irritation/redness), and ease of use, impacting compliance.

Sharpe E D, Henry C J, Mundorf T K, Day D G, Stewart J A, Jenkins J N et al.

Adding brimonidine or unoprostone to timolol showed similar IOP-lowering efficacy and safety in glaucoma patients, but unoprostone caused more burning and dryness. This suggests comparable clinical utility.

Stewart W C, Stewart J A, Day D G, Sharpe E D, Jenkins J N

This study found latanoprost/timolol fixed combination and concomitant latanoprost/brimonidine offer similar overall IOP reduction in glaucoma, though concomitant therapy showed slightly lower IOP at midday.

Stewart W C, Day D G, Stewart J A, Holmes K T, Jenkins J N

Dorzolamide caused more immediate ocular pain/stinging than brinzolamide or placebo in glaucoma patients, but this effect lessened with chronic use and was generally mild.

Sharpe E D, Day D G, Beischel C J, Rhodes J S, Stewart J A, Stewart W C

This study found brimonidine purite and dorzolamide similarly lowered IOP in glaucoma/ocular hypertension, but dorzolamide caused more stinging. Both are effective, but tolerability may differ.

Stewart W C, Day D G, Holmes K T, Stewart J A

This study found timolol 0.5% (solution or gel) did not worsen pulmonary function in older glaucoma patients without reactive airway disease, suggesting its safe use in this population.

Stewart W C, Day D G, Stewart J A, Schuhr J, Latham K E

Latanoprost once daily lowered IOP more effectively than brimonidine twice daily in glaucoma/ocular hypertension patients, suggesting superior pressure control, though latanoprost caused more hyperemia.

Stewart W C, Kolker A E, Sharpe E D, Day D G, Holmes K T, Leech J N et al.

This study found higher average and fluctuating IOP, larger cup-to-disk ratio, age, and more medications are risk factors for long-term POAG progression, emphasizing IOP control's importance despite its variable effectiveness.

Stewart W C, Sharpe E D, Harbin T S, Pastor S A, Day D G, Holmes K T et al.

This study found brimonidine and dorzolamide provided similar IOP reduction in glaucoma/ocular hypertension, but dorzolamide caused more stinging and brimonidine more itching, indicating comparable efficacy with different side effect profiles.

Stewart W C, Day D G, Sharpe E D, Dubiner H B, Holmes K T, Stewart J A

This study found once-daily timolol solution and gel are equally effective and safe as adjunctive therapy to latanoprost for glaucoma, providing similar 24-hour intraocular pressure reduction.